Drugs / MSX-122
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00591682 | Nov 2007 → Dec 2008 | cancer | Metastatix, Inc. | Suspended | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MSX-122 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00591682 ↗ |
| Action | Inhibit | “C-X-C chemokine receptor type 4 antagonist” CHEMBL3545330 ↗ |
| Modality | Small molecule | — CHEMBL3545330 ↗ |
| Route | Oral | “50 mg taken orally once daily” NCT00591682 ↗ |
| Target | CXCR4 | “C-X-C chemokine receptor type 4 antagonist” CHEMBL3545330 ↗ |